Summary
Acambis' main focus is to develop and commercialize products for the treatment of infectious and other biological diseases. The company was originally created as a company that focused on building a franchise of biodefence products through its own internal efforts to develop and commercialize therapeutics for the treatment of smallpox and other infectious diseases. Scope
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Acambis has three investigational drug candidates in clinical programs, namely, ChimeriVax-West Nile, C difficile and Influenza vaccine. ChimeriVax-West Nile, a vaccine against the West Nile virus, is currently undergoing second part of Phase II trials.
C difficile, a vaccine against the hospital-acquired Clostridium difficile bacterium, is undergoing Phase I trials and is expected to enter Phase II trials. Influenza vaccine, a vaccine that targets all strains of the influenza virus, is undergoing preclinical trials.
Acambis derives its revenues from product sales of ACAM2000, MVA3000 and income derived from contract research fees and license fees receivable from third parties in the normal course of business. The company's total revenues decreased at a CAGR of 21% during 2002-2006, from $151 million to $58 million. Reasons to Purchase
- Access all the important information and analysis on the company in a single report
- Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to company's adjusted five year financial data along with key ratios and market capitalization
|
Content
- Table Of Contents
- Overview
- Catalyst
- Summary
- Company Structure
- Company Overview And Key Facts
- Business Description
- History
- Locations And Subsidiaries
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Geographic Segment Performance
- Products & Services
- Pipeline Products
- Ac Forecast Product Sales
- Competitors And Strategic Business Relationships
- Key Competitors
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- Swot Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Discovery And Product Development
- Manufacturing
- Sales
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- Key Employee Biographies
- Financial And Operational Overview
- Financial And Operational Overview
- Appendix
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
- Table Of Figures
- Figure 1: Acambis - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table Of Tables
- Table 1: Acambis - Key Facts
- Table 2: Acambis - Other Locations And Subsidiaries
- Table 3: Acambis - Year-End Share Price And Market Capitalization, 2002-2006 ($)
- Table 4: Acambis - Key Events Impacting Share Price Performance
- Table 5: Acambis - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 6: Acambis - Operating Cost Ratio Analysis, 2002-2006 (% Of Total Revenues)
- Table 7: Acambis - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: Acambis - Cash Flow, 2002-2006 ($ Mn)
- Table 9: Acambis - Geographic Breakdown, 2002-2006 ($ Mn)
- Table 10: Acambis - In-House Pipeline Products
- Table 11: Acambis - Collaboration Pipeline Products
- Table 12: Acambis - Forecast Sales, 2006-2010 ($ Mn)
- Table 13: Acambis - Key Competitors
- Table 14: Acambis - Key Clients
- Table 15: Acambis - Key Shareholders
- Table 16: Acambis - Swot Analysis Summary
- Table 17: Acambis - Value Chain Analysis
- Table 18: Acambis - Scorecard
- Table 19: Acambis - Key Employees
- Table 20: Acambis - Financial And Operational Overview
|
